PD-404182 is an inhibitor of bacterial 2-keto-3-deoxyctulosonic acid (KDO) 8-P synthase. It is a virucidal compound that compromises the structural integrity of both hepatitis C virus and human immunodeficiency virus, likely by interacting with a nonlipid structural element of these viruses. In vitro studies revealed that PD-404182 physically disrupts variously pseudotyped lentiviruses and exposes the viral genomic RNA in a time- and temperature-dependent manner. Also, PD-404182 might be a tightly bound, covalent, or an irreversible inhibitor of human dimethylarginine dimethylaminohydrolase 1.

PD 176252 is a competitive antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide preferring (BB2) receptors. PD176252 inhibited tumor growtn in preclinical model of lung cancer, and exhibited synergy with EGFR inhibitor in the model of head and neck cancer. PD176252 demonstrated anxiolytic properties in preclinical models.

PD 173212 is a potent, selective N-type voltage-gated Ca2+ channel blocker (IC50 = 36 nM), it possesses selectivity for non L-type Ca ÷2 channels versus neuronal Na ÷, K ÷, and L-type Ca ÷2 channels. PD 173212 demonstrated potent in vitro activity in the IMR-32 assay as well as in electrophysiology, and it was efficacious in the audiogenic seizure mouse model.